Background: Cytoreductive surgery with intraperitoneal hyperthermic chemoperfusion (IPHC) has evolved into a promising approach for peritoneal surface malignancy. A large body of literature suggests that oxaliplatin has excellent cytotoxicity against colorectal cancer. Therefore, we undertook a phase I evaluation of IPHC with oxaliplatin for peritoneal dissemination from colorectal and appendiceal cancers to establish the dose-limiting toxicity (DLT) and the maximum tolerated dose (MTD).
generally provides limited benefit. 1, 3 The use of cytoreductive surgery along with intraperitoneal hyperthermic chemotherapy (IPHC) however, has evolved into an a promising approach for peritoneal surface malignancy. [4] [5] [6] [7] IPHC provides a pharmacokinetic advantage to the treatment of local-regional disease relative to systemic therapy because it bypasses the peritoneal-plasma partition. 8, 9 A unique challenge is to identify agents that offer optimal therapeutic benefits while minimizing toxicity. Although a variety of agents have been investigated for use in the setting of IPHC for the treatment of peritoneal dissemination of colorectal and appendiceal cancers, most have either limited activity against colorectal cancer or lack additional therapeutic effect from the addition of hyperthermia. Mitomycin C is the most commonly utilized agent for IPHC and has been used since the early 1990s. The availability of newer and potentially more active agents suggests a potential for improved efficacy.
Oxaliplatin is a diaminocyclohexane-platinum compound that is active in a variety of solid tumor types and is licensed in the USA for the treatment of colorectal cancer. Oxaliplatin is an attractive agent for IPHC because it not only has proven activity against colorectal cancer cells, 10 but it is also potentiated by hyperthermia. Previous data demonstrate that the concentration of oxaliplatin required to induce cytotoxicity is significantly reduced when delivered in the context of hyperthermia. 11, 12 In a preliminary set of experiments from our group, hyperthermia sensitized both HCT-29 and RKO cell lines to the cytopathic affects of oxaliplatin. The oxaliplatin IC 50 for HCT 116 and RKO colorectal cancer cells was reduced from 144 lM and 89 lM to 57 lM and 59 lM, respectively, after exposing these cell lines to mild hyperthermia at 40°C for 2 h (unpublished data from the laboratory of John Stewart). The superior cytotoxicity of oxaliplatin makes it an excellent drug to study in the setting of peritoneal surface dissemination of colorectal and appendiceal cancers. Therefore, we initiated this dose escalation trial to evaluate the safety of using oxaliplatin in the perfusate for intraperitoneal hyperthermic chemotherapy at the time of cytoreductive surgery.
PATIENTS AND METHODS

Patient Eligibility
All patients were older than 18 years with histologically confirmed colorectal or appendiceal cancer and had an Eastern Cooperative Group performance status of 0-2. Acceptable bone marrow (absolute neutrophil count ‡1,500/lL, platelet count ‡ 100,000/ lL), renal (serum creatinine £1.5), and hepatic function (serum total bilirubin £1.5 mg/dL, alkaline phosphatase £3· the upper limit of normal, and serum oxaloacetic transaminase (SGOT)/serum glutamic pyruvic transaminase (SGPT) £3· the upper limit of normal) were required for enrollment in this trial. Ineligibility criteria included an active infection or a fever ‡38.5°C within 3 days of the scheduled day of protocol treatment, central nervous system metastases, known hypersensitivity to any of the components of oxaliplatin, receipt of investigational therapy within 30 days of IPHC (investigational therapy was defined as treatment for which there is currently no regulatory authority approved indication), peripheral neuropathy ‡ grade 2, history of allogeneic transplant, and known HIV or hepatitis B or C infection. Patients with prior malignancy within the past 5 years were considered to be ineligible except for curatively treated basal cell carcinoma of the skin, cervical intra-epithelial neoplasia, or localized prostate cancer with a current prostate specific antigen (PSA) of\1.0 mg/dL on two successive evaluations.
Study Design
This was a nonrandomized, open-label phase I trial in patients with stage IV peritoneal carcinomatosis from colorectal and appendiceal cancers. This trial was reviewed and approved by the Wake Forest University Health Sciences Institutional Review Board. All patients signed a written informed consent prior to study enrollment. The dose escalation scheme was based on a modified Fibonacci series. Dose-limiting toxicity (DLT) was defined as grade 3 toxicity that was attributable to the intraperitoneal administration of oxaliplatin and exceeded 5 days in duration. Three patients were assigned to a dose of 200 mg/M 2 of oxaliplatin, which is roughly 2.5 times the intravenous dose delivered to patients with metastatic colorectal cancer, to verify that this dose would be tolerated in patients with peritoneal carcinomatosis. We then proceeded to escalate to the next dose level of 250 mg/M 2 after at least 10 days elapsed since the completion of the first cohort to rule out unacceptable DLT. Two of three patients demonstrated DLTs in this cohort, so 200 mg/M 2 was considered the maximum tolerated dose (MTD). After defining the MTD, an additional nine patients were enrolled to more fully evaluate toxicities and pharmacokinetics at 200 mg/M Adverse events were described using the National Cancer Institute Common Terminology (NCI CT3.0) criteria. Frequency and severity of adverse events were described according to the NCI CTCAE V 3.0 body system and severity criteria. In addition, the frequency of grade 3 or 4 adverse clinical events and laboratory abnormalities as well as causality were recorded according to the NCI CTCAE criteria.
Study Procedures
All participants underwent preoperative mechanical and antibiotic bowel preparation. Potential ostomy sites were marked by the surgeon or the enterostomal nurse prior to surgery. The IPHC was preceded by a complete cytoreduction to maximize its therapeutic benefit, as described elsewhere. 5 The goal of cytoreductive surgery was to render the patient free of disease. Resection of the peritoneum by stripping it off the abdominal wall combined with multivisceral resections, as indicated by disease adherent to intra-abdominal organs (such as splenectomy, large and small bowel resection, uterus, etc.), were utilized for maximal tumor debulking. All patients in this study had 2 cm of tumor and 2 cm of normal peritoneum marked and left in place during the IPHC and removed immediately after perfusion to evaluate tissue drug levels.
Patients were cooled to a core temperature of about 34-35°C by passive measures during cytoreduction. After the completion of cytoreductive surgery, peritoneal perfusion catheters were placed percutaneously. Two inflow catheters (22 F) were directed beneath the left and right hemidiaphragms. Two outflow catheters (32 F) were placed in the pelvis. Drainage bulbs were attached to the end of the outflow cannulae to avoid suction injury to the bowel. Temperature probes were placed on the inflow and outflow catheters. The abdominal skin incision was temporarily closed with a running suture to prevent leakage of peritoneal perfusate. A perfusion circuit was then established with 3 L of D5W solution. Flow rates of approximately 800-1,000 mL/min were maintained using a roller pump managed by a perfusionist. The pelvic catheters drained to a standard cardiotomy reservoir containing a coarse filter for debris and to reduce foaming. The circuit continued through a single roller pump, a heat exchanger, and then to the patient. Heated water was be pumped to the heat exchanger device from a Blanketrol Ò (Cincinnati Sub-Zero Products, Inc., Cincinnati, OH) heating/cooling blanket reservoir. The temperature of the fluid in the patient, water bath, patient-return, and patient-directed tubing were monitored using stainless-steel couplers with temperature probe connectors and needle probes at the tips of one inflow and one outflow cannula.
Once outflow temperatures exceeded 39°C, oxaliplatin was added to the perfusate. A maximum inflow temperature of 42.5°C was tolerated during the perfusion, with a target outflow temperature of 40°C. The total perfusion time after the initial addition of oxaliplatin was 120 min. The abdomen was gently massaged throughout the perfusion to improve drug distribution to all peritoneal surfaces. Following the perfusion, the peritoneum was washed out with 3 L of crystalloid and the peritoneum drained passively. The skin was then opened, and the cannulae removed under direct vision. The previously marked residual tumor was resected after the perfusion and submitted for tissue and intratumoral oxaliplatin levels. The abdomen was inspected and the required anastomoses or stomas were performed. The fascia and skin were then closed in a standard fashion.
Pharmacokinetics Methods
Each patient had 20 heparinized blood samples of 5 mL drawn during the study for pharmacokinetics studies. The samples were drawn at time 0 and at 10-min increments until the completion of the perfusion. Samples were also collected at 10, 20, 30, 60, and 90 min and at 12 and 24 h after IPHC. Five milliliters of peritoneal fluid samples were collected at time 0 and at 10-min increments until the completion of the perfusion. The samples were stored at -70°C until analysis.
Two types of tissues were collected before and after the IPHC. Before the perfusion with oxaliplatin, a 2-cm-diameter piece of normal peritoneum and samples of peritoneal surface malignancy were collected for pharmacokinetic analysis. Upon completion of the perfusion, another 2 cm sample of peritoneum as well as the tumor nodule which was marked and left in situ during the perfusion were collected for analysis of oxaliplatin levels. All tissue was snap-frozen in liquid nitrogen and stored at À70°C until analysis.
Platinum levels were determined by inductively coupled plasma atomic emission spectrometry (Thermo iCAP 6500 ICP-OES). A 1.00 mL aliquot of each fluid sample was added to a 15 mL digestion tube. The samples were acidified with 0.50 mL concentrated nitric acid and 0.50 mL concentrated hydrochloric acid. The solution was shaken with a vortex device, and then heated in a water bath at 90°C for 1 h. After cooling, the final solution volume was made up to 5.0 mL with deionized water, so the overall dilution factor for the original fluid sample was 5. Finally, the diluted samples were centrifuged for 30 min at 3000 rpm, and the supernatant was analyzed.
Tissue sample mass ranging from 0.005 to 0.200 g was determined accurately with an analytical balance. The samples were added to a 50 mL digestion tube, and acidified with 2.5 mL concentrated nitric acid and 2.5 mL concentrated hydrochloric acid. The acid solutions were heated on a hot block for 12 h at 60°C. The samples were then diluted to 25.0 mL before being analyzed by inductively coupled plasma atomic emission spectrometry.
All pharmacokinetics values were calculated using OriginPro 8 SR1 (Hearne Scientific Software, Chicago, IL). The area under the curve (AUC) was determined numerically by using two adjacent values to form a trapezoid, and the area of all of the trapezoids was then calculated. The half-life of platinum was calculated by fitting an exponentially decaying function from the peak concentration of platinum.
Statistical Analysis
Descriptive statistics, including frequencies and proportions for categorical data and means, standard deviations, and ranges for continuous measures, were calculated. Categorical data were analyzed using a Fisher's exact test (an exact form of the chi-square), while continuous data were analyzed using a Wilcoxon two-sample test (this test takes into account small sample sizes in the study groups). A P-value less than 0.05 indicated significant differences in the outcome measure between the two study groups.
RESULTS
Patient Demographics
Fifteen patients were enrolled between March 22, 2007 and November 19, 2007. Twelve patients were enrolled at the 200 mg/M 2 dose while three were enrolled at the 250 mg/M 2 dose. Table 1 lists patient demographics and baseline data. The treatment groups were essentially identical with respect to patient characteristics. The mean age was 55.5 ± 10.9 years (range 39-73 years) with a slight female preponderance. Most of the patients enrolled in this study had appendiceal tumors. The majority of patients enrolled in this trial underwent treatment of their disease prior to enrollment in this trial. Seven patients were treated with previous chemotherapy (six were treated with systemic oxaliplatin) while one patient had undergone prior IPHC with mitomycin C. 
SD, standard deviation.
Operative and Perfusion Data
The operative and perfusion data are summarized in Table 2 . The length of the operation (range 363-715 min) was primarily related to the extent and location of disease at exploration. The goal of cytoreductive surgery was to render the patient free of disease. This varied from simple lysis of adhesions and omentectomy to multivisceral resections in other instances. The quantity of residual disease was recorded by the primary surgeon; the resection status of all patients undergoing IPHC on this protocol is listed in Table 2 . The mean outflow temperature of the perfusate in this study was 40.6 ± 0.5°C. Patients received an average of three units of packed red blood cells during the debulking portion of the procedure. This reflects the magnitude of the cytoreductive procedures required to render these patients free of macroscopic disease.
Toxicity
Three patients were initially assigned to a dose of 200 mg/M 2 of oxaliplatin to verify that this dose would be tolerated in patients with peritoneal carcinomatosis. We then proceeded to escalate to the next dose level of 250 mg/M 2 . Enrollment in the second cohort was stopped after two patients developed DLTs lasting longer than 5 days. One patient experienced profound leukopenia on postoperative day 2 that was resistant to granulocyte colony stimulating factor. This patient also experienced grade 5 thrombocytopenia and died of bone marrow suppression on postoperative day 4. An additional patient in the second cohort presented with grade 3 thrombocytopenia that resolved after 1 week. With 2/3 patients experiencing high-grade toxicity at this dose level, nine additional patients were enrolled into the 200 mg/M 2 cohort and no DLTs were observed in these patients. Therefore, 200 mg/M 2 represented the MTD for this study.
The cumulative experience of clinical toxicity occurring in all 15 patients is summarized in Table 3 . Peritoneal delivery of 200 mg/M 2 of oxaliplatin was well tolerated. Patients in this cohort experienced minor, short-lived toxicities with the most common toxicity being thrombocytopenia. Although grade 1 or 2 leukopenia occurred in a third of the patients in the first cohort, it uniformly resolved without cytokine support. A few grade 3 and 4 toxicities were seen in patients treated with 200 mg/M 2 of oxaliplatin, but these toxicities resolved in fewer than 5 days and were therefore not considered DLTs.
Pharmacokinetics
An important aspect of understanding the feasibility of utilizing oxaliplatin as the chemotherapeutic agent for IPHC is defining the pharmacokinetic profile of this drug during a 2-h peritoneal perfusion. Figure 1 demonstrates the concentration of platinum in the peritoneal perfusate over time, while Table 4 delineates the pharmacokinetics of intraperitoneal oxaliplatin during IPHC. Despite significant interindividual variation, the maximum concentration of oxaliplatin in the perfusate was seen at the beginning of the perfusion and it gradual decreased to 14.0 ± 4.3 mg/L in the 200 mg/M 2 cohort and 15.9 ± 2.9 mg/L in patients treated at the 250 mg/M 2 dose level. The drug half life (t 1/2 ) in cohorts 1 and 2 were similar at 70.1 ± 23.8 min and 65.3 ± 10.2 min, respectively. During IPHC, peritoneal exposure to the drug, as defined by the AUC, was 49.6 ± 8.6 mg/L h Figure 2 demonstrates the concentration of platinum in the plasma over 24 h. Additionally, Table 4 presents the pharmacokinetics of oxaliplatin both during and after IPHC. The maximum concentration of platinum in plasma was seen at 70 min for both cohorts. The peak plasma concentration of platinum for patients treated at 200 mg/M 2 was 2.2 ± 0.77 mg/ L while that for patients treated at 250 mg/M 2 was 3.2 ± 0.6 mg/L (P = 0.03). Thereafter, plasma platinum concentrations slowly decreased at a t 1/2 of 94.2 ± 64. Leukocytes  4  33  0  0  2  67  1  33  Platelets  6  50  1  8  0  0  2  67  Hemoglobin  2  17  2  17  0  0  2  67  Nausea  3  25  0  0  2 Values are expressed as the mean ± standard deviation. t 1/2 , half life; C max , maximum concentration of drug; C min , minimum concentration of drug; AUC, area under the curve. cohort was 23.2 ± 11.4 mg/L h while that for the 250 mg/M 2 cohort was 31.1 ± 3.0 mg/L h. In contradistinction to the AUC data presented for peritoneal fluid, the plasma time points encompass the entire 24-h treatment period. As is shown in Table 5 , dramatic increases in tumor, peritoneal, and normal tissue was seen at 2 h. Interestingly, tissue platinum levels were 25 to 32-fold those seen in the plasma at the conclusion of IPHC.
Analysis of intraoperative pharmacokinetics of oxaliplatin in the peritoneal fluid and plasma during IPHC are shown in Table 6 . When evaluated over the course of IPHC, the AUC of peritoneal fluid was 13.7 ± 4.7 fold higher than that of plasma in cohort 1 and 12.8 ± 3.1 fold higher in cohort 2. The platinum AUC of the peritoneal fluid during the course of the IPHC was significantly higher for the 250 mg/M 2 cohort than the 200 mg/M 2 cohort (49.6 ± 8.6 mg/ L h versus 62.7 ± 10.2 mg/L h , P = 0.036). Similar findings were noted for the plasma AUC (3.6 ± 1.2 mg/L h versus 4.9 ± 0.54 mg/L h, P = 0.036). During the first hour of IPHC, the oxaliplatin AUC was 20.0 ± 6.6 times higher in peritoneal fluid than plasma for cohort 1 and 21.5 ± 3.1 times higher in peritoneal fluid than plasma for cohort 2. As the IPHC progressed to 2 h, the pharmacokinetic advantage was slightly diminished to 9.1 ± 3.9 fold in the 200 mg/M 2 cohort and 7.8 ± 1.6 fold in the 250 mg/M 2 cohort.
CONCLUSIONS
The clinical utility of cytoreductive surgery and IPHC for peritoneal dissemination of colorectal and appendiceal cancer has been previously described. 4, 6, 7 Oxaliplatin is particularly attractive for the treatment of peritoneal carcinomatosis. It is much more active against colorectal cancer than mitomycin C, which has been the most commonly utilized agent. In addition, oxaliplatin's antineoplastic activity is potentiated by hyperthermia, unlike that of 5-fluorouracil.
Prior studies from France have evaluated oxaliplatin for IPHC; however, these studies used a 30-min perfusion at 42-44°C. The MTD was found to be 460 mg/M 2 . 13 Our group has attempted to apply this dose to IPHC as commonly practiced in the USA. Significant hematologic and gastrointestinal toxicities were noted, hence warranting additional evaluation. In contradistinction to previous studies, we reevaluated the dosing of oxaliplatin by employing a 2-h perfusion at outflow temperatures of approximately 40°C using a closed abdomen technique, as has been our practice since 1991. Given the differences in technique and MTD, it is important to consider our results in the context of the previously reported studies of IPHC with oxaliplatin.
The rationale for IPHC lies in the limited entry of systemic chemotherapy into the peritoneum due to the plasma-peritoneal partition. Drugs delivered into the peritoneal cavity have a clearance that is inversely proportional to the square root of their molecular weight. 8, 9 Because of this partition, drugs without lipophilic properties and high molecular weight have optimal pharmacokinetic profiles for intraperitoneal application. In the present study, we detailed the pharmacokinetic profile of oxaliplatin delivered via a 2-h hyperthermic chemoperfusion. Our data demonstrate three important points with respect to the pharmacokinetic profile of intraperitoneal oxaliplatin. First, peritoneal delivery of oxaliplatin provides a significant treatment advantage to tumor tissue. Tumor cells contained 22-to 25-fold more drug than did plasma at the conclusion of IPHC, thereby confirming the preferential delivery of oxaliplatin to the tumor cells compared to plasma. Second, tissue exposure to oxaliplatin in the perfusate significantly decreases during IPHC. The intraperitoneal tissue exposure to chemotherapy during IPHC is best described by the AUC peritoneum/plasma value. At 200 mg/M 2 , the total AUC peritoneum/plasma was 13.7 ± 4.7 whereas it was 12.8 ± 3.1 at the 250 mg/M 2 dose. Interestingly, if one compares the AUC peritoneum/plasma for the first half of the procedure to that of the second half, one realizes that the ratio drops significantly. This drop is due to slow accumulation of drug in the plasma and falling peritoneal drug concentration. From these data, one can conclude that the 200 mg/M 2 dose of oxaliplatin may best be delivered in divided doses during peritoneal perfusion. Alternatively, a 90-min perfusion could be considered as a small fraction of the AUC occurring in the final 30 min of a 2-h perfusion. Finally, the data presented in this trial demonstrate that oxaliplatin has a less favorable pharmacokinetic profile than mitomycin C for IPHC. In the present study, the AUC peritoneum/ plasma value was 13.7 ± 4.7 whereas early pharmacokinetic studies of mitomycin C report a AUC peritoneum/plasma value of 75. 14 However, due to oxaliplatin's direct activity on the nucleus, it has a steep doseeffect curve; therefore this gradient can have significant therapeutic implications. 15 In future trials we hope to delineate these therapeutic implications in a prospective, randomized manner.
Intraperitoneal delivery of oxaliplatin was well tolerated in this group of patients. Patients treated at the 200 mg/M 2 dose experienced few short-lived toxicities, which did not require intervention. In the present study, 1 of 12 patients exhibited grade 1 neutropenia that spontaneously resolved in 3 days. Although all patients in the 200 mg/M 2 cohort demonstrated lymphopenia, this may not be entirely attributable to oxaliplatin since lymphopenia has been described after a variety of operative procedures. [16] [17] [18] Additionally, 6 of 12 patients experienced grade 1 or 2 thrombocytopenia and 1 participant experienced grade 3 thrombocytopenia that resolved without the need for transfusion. These findings compare favorable to the 30% hematologic toxicity in patients treated with mitomycin-C-based IPHC. 7, 19 Perhaps the differences in toxicity are related to the propensity of mitomycin C to induce neutropenia and thrombocytopenia. 20 This issue can only be resolved in a prospective trial that evaluates hematologic toxicities in patients treated with 200 mg/M 2 oxaliplatin to those treated with 40 mg mitomycin C. Compared to previous trials with 460 mg/M 2 , oxaliplatin resulted in a hematologic toxicity rate of approximately 20%. The higher hematologic toxicity rate in these studies is likely related to greater systemic absorption of oxaliplatin at the higher dose. The maximal plasma concentration of total oxaliplatin was approximately 12 mg/L in prior studies. 13, 21 However, the maximal plasma concentration was 2.16 mg/L in our study. These differences in maximal plasma concentration of oxaliplatin could therefore account for the differences in toxicities at the two dose levels.
The majority of the clinical benefit from cytoreductive surgery and IPHC is clearly from resection. However, efforts to optimize the perfusion seem clearly warranted. Whether oxaliplatin results in improved outcomes remains to be seen. However, the impressive outcome results for systemic administration suggest a realistic likelihood of efficacy.
The present data support the use of oxaliplatin at 200 mg/M 2 for IPHC in the treatment of peritoneal dissemination of colorectal and appendiceal cancers. This treatment regimen is safe and feasible at 200 mg/ M 2 . The toxicity appears lower than our previous experience with mitomycin C. Based on these findings, we plan to propose a larger study that compares toxicity and outcome of patients treated with mitomycin C to those treated with oxaliplatin.
